Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Hepatocellular

Explore clinical trials studying Carcinoma, Hepatocellular. Study availability and eligibility vary by location and protocol.

182 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Hepatocellular trial results

Completed

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

NCT00554372

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
Locations
  • Moores UCSD Cancer Center La Jolla, California, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Billings Clinic Cancer Center Billings, Montana, United States
  • The Ohio State University Columbus, Ohio, United States
View Trial Details
Completed

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Arizona Oncology Associates PC- HOPE ( Site 0770) Tucson, Arizona, United States
  • Scripps Clinic Torrey Pines ( Site 0714) La Jolla, California, United States
  • USC Norris Comprehensive Cancer Center ( Site 0717) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0720) Los Angeles, California, United States
View all 205 locations
View Trial Details
Completed

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • The University of Arizona Cancer Center - North Campus ( Site 0621) Tucson, Arizona, United States
  • City of Hope Comprehensive Cancer Center ( Site 0587) Duarte, California, United States
  • Scripps Health ( Site 0644) La Jolla, California, United States
  • Pacific Hematology Oncology Associates ( Site 0588) San Francisco, California, United States
View all 172 locations
View Trial Details
Completed

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

NCT05337137

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
Locations
  • Local Institution - 0042 Los Angeles, California, United States
  • Local Institution - 0039 Los Angeles, California, United States
  • Local Institution - 0034 San Francisco, California, United States
  • Local Institution - 0030 Washington D.C., District of Columbia, United States
View all 61 locations
View Trial Details
Completed

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

NCT05908786

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
Locations
  • University of Southern California (USC) Los Angeles, California, United States
  • University of California Los Angeles (UCLA) - Cancer Care - Santa Monica Santa Monica, California, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus Detroit, Michigan, United States
View all 30 locations
View Trial Details
Completed

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

NCT05091346

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +28 more
Locations
  • University of California, Los Angeles Los Angeles, California, United States
  • University of California, Irvine Health Orange, California, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • SCRI Florida Cancer Specialists East West Palm Beach, Florida, United States
View all 32 locations
View Trial Details
Completed

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

NCT03062358

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Anhui Provincial Hospital ( Site 0032) Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0005) Hefei, Anhui, China
  • Fuzhou General Hospital of Nanjing Military Command ( Site 0019) Fuzhou, Fujian, China
  • The First People s Hospital of Foshan ( Site 0033) Foshan, Guangdong, China
View all 41 locations
View Trial Details

Related conditions